Skip to content

Comparison between Effect of autologous plasma therapy local infiltration and Local infiltration with gel application in diabetic foot ulcer patients

Comparative study of the effect of different modalities of autologous platelet rich plasma(APRP) therapy in treating chronic diabetic foot ulcers(DFUs) - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/088086
Enrollment
60
Registered
2025-06-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L00-L99- Diseases of the skin and subcutaneous tissue

Interventions

Intervention1: Autologous platelet rich plasma therapy: We will take whole blood of 10-40ml according to wound size and platelet rich plasma will be separated and used over diabetic foot ulcers.APRP

Sponsors

Department of general surgery Aiims Deoghar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age from 18 -80.Both gender.Non healing ulcer (diabetic) more than 6 weeks.Ulcer of grade I and II (Wagner grade).Ulcer of size more than 1 cm and less than 10cm and depth less than 2 cm.Blood sugar range 150-200 gm/dl and HbA1C level 6.5 to 8 mg/dl g) Patient agrees to donate blood in order to prepare autologous platelet-rich plasma h) Consent to participate in study

Exclusion criteria

Exclusion criteria: Non diabetic non-healing ulcers (like pressure sores, Venous ulcer and malignant ulcers).Infected and gangrenous DFUs( Evidence of osteomyelitis in the affected foot & Exposed tendons, ligaments, or bones at the base of ulcer. Patient with Platelet dysfunction disorder ,CKD, thrombocytopenia, pregnant and lactating , taking NSAIDS and steroids. Patients who received radiotherapy or chemotherapy at the time of study or within 3 months of its beginning. Patients with hypersensitivity and/or allergy to any of the components of treatment product

Design outcomes

Primary

MeasureTime frame
Reduction of wound sizeTimepoint: 12 weeks

Secondary

MeasureTime frame
Rate of wound healingTimepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Amardeep Kumar

Aiims Deoghar

drharaprasad1997@gmail.com8093141108

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026